奥芬达唑(Oxfendazole) - 在研适应症：神经系统囊虫病，片形吸虫病，鞭虫病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(5-(phenylsulfinyl)-1H-benzimidazol-2-yl)carbamic acid methyl ester、5-(phenylsulfinyl)-2-benzimidazolecarbamic acid methyl ester、5-phenylsulfinyl-2-carbomethoxyaminobenzimidazole

+ [8]

靶点-

作用机制-

治疗领域

感染神经系统疾病其他疾病+ [3]

在研适应症

神经系统囊虫病片形吸虫病鞭虫病+ [3]

非在研适应症-

原研机构

National Institute of Allergy & Infectious Diseases

在研机构

The Oxfendazole Development Group

Drugs for Neglected Diseases initiativeUniversidad Peruana Cayetano Heredia

+ [1]

非在研机构-

最高研发阶段临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构

分子式C15H13N3O3S

InChIKeyBEZZFPOZAYTVHN-UHFFFAOYSA-N

CAS号53716-50-0

关联

9

项与奥芬达唑相关的临床试验

NCT06367361 / Not yet recruiting临床2期IIT

Non-inferiority, Controlled, Randomized, Single-blind Study for Compare Regimens of One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole to Treat Chronic Fascioliasis

Randomized clinical trial comparing the efficacy and safety of oxfendazole at 20 mg/kg per dose in one and two dose regimens with a two-dose regimen of triclabendazole at 10 mg/kg in an endemic region of the highlands of Peru. Children and adults with fascioliasis in rural communities will be screened for inclusion and exclusion criteria and a total of 336 subjects (112 per study arm) with chronic Fasciola infection will be enrolled and assigned randomly to the study arms in a 1:1:1 ratio. The primary efficacy (cure and egg reduction) endpoints will be assessed on day 7 and 30 post treatment. The secondary safety endpoint visits will be performed in days 0, 3, 7 and 30 post-treatment and Population Pharmacokinetics (PK) modeling studies will be performed in the first 24 hours after the first dose of oxfendazole.

开始日期2025-01-30

申办/合作机构

Universidad Peruana Cayetano Heredia

[+2]

NCT06565507 / Not yet recruiting临床2/3期IIT

A Double-blind Multicenter, Randomized Controlled Trial of Single and Multiple Dose Regimens of Oxfendazole for Mild (One or Two Lesions) Parenchymal Brain Cysticercosis, With an Open Comparison Group

The goal of this clinical trial is to compare a single and multiple dose regimens of oxfendazole with the standard treatment in patients with mild (one or two lesions) parenchymal brain cisticercosis. The main question it aims to answer is if OXF will enhance clearance of brain parasites and therefore provide greater cysticidal efficacy, with the potential to provide a single-dose therapy for this type of NCC.
The study cohort will also allow us to identify early imaging markers that predict lesion resolution, as well as factors associated with residual calcification or focal gliosis after lesion resolution. This study will also provide additional information on the safety of the study interventions.

开始日期2024-12-15

申办/合作机构

Universidad Peruana Cayetano Heredia

[+1]

NCT03435718 / Not yet recruiting临床2期IIT

An Assessor Blind, Randomized, Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults

The main objective of this study is to provide data on the efficacy profile of different doses of oxfendazole when used in Trichuris trichiura infection. The drug will be also be examined for efficacy against other common nematodes encountered in man (Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus). The study will also provide data on the safety and tolerability of the oxfendazole in patients.

开始日期2024-07-01

申办/合作机构

The Oxfendazole Development Group

[+1]

100 项与奥芬达唑相关的临床结果

登录后查看更多信息

100 项与奥芬达唑相关的转化医学

登录后查看更多信息

100 项与奥芬达唑相关的专利（医药）

登录后查看更多信息

1,595

项与奥芬达唑相关的文献（医药）

2024-12-06·Journal of Biomolecular Structure and Dynamics

Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer

Article

作者: Nidhi ; Khan, Imran A. ; Khan, Mohd Ashif ; Reeta ; Garg, Aakriti ; Karhana, Sonali ; Bano, Aysha

Emerging studies have reported the potential anticancer activity of benzimidazole-based anthelmintics (BBA) against lung cancer (LC). However, mechanism underlying the anticancer activity of BBA is unclear. Therefore, in the current study, network pharmacology and molecular docking-based approach were used to explore the potential molecular mechanism for the treatment of LC. The potential targets for BBA were obtained from multiple databases including SwissTargetPrediction, Drug Bank, Therapeutic Target Database, and Comparative Toxicogenomics Database while LC targets were collected from DisGeNet gene discovery platform, Integrated Genomic Database of NSCLC, Catalogue of Somatic Mutations in Cancer and Online Mendelian Inheritance in Man database. Protein-protein interaction (PPI) diagram of common targets was constructed using STRING online platform. Topological analysis was performed using Cytoscape and gene enrichment analysis was conducted using FunRich software. Highest degree targets were then confirmed using molecular docking and molecular dynamics simulations. The BBA were prioritized according to their S scores, with ricobendazole ranking highest followed by flubendazole, fenbendazole, mebendazole, triclabendazole, albendazole, oxibendazole, parbendazole, thiabendazole and oxfendazole. The potential targets of BBA identified using topological analysis and molecular docking were found to be CCND1 (cyclin D1), EGFR (Epidermal Growth Factor Receptor), ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2/CD340), PTGS2 (Prostaglandin-endoperoxide synthase 2), and SRC (Proto-oncogene tyrosine-protein kinase). Furthermore, molecular dynamics confirmed that CCND1 and EGFR are the potential targets of ricobendazole for the treatment of LC. BBA can be further explored as a therapeutic strategy for the treatment of lung cancer under in vitro and in vivo studies.Communicated by Ramaswamy H. Sarma.

2024-12-01·International Journal for Parasitology: Parasites and Wildlife

Response of Northern bobwhite (Colinus virginianus) and two parasitic nematode populations in western Oklahoma to anthelmintic supplemental feed

Review

作者: Kendall, Ronald J. ; Lukashow-Moore, Shannon P. ; Suber, Hannah N. ; Suber, Hannah N ; Conley, Katelyn A. ; Conley, Katelyn A ; Rivera, Regan ; Surles, James G. ; Surles, James G ; Lukashow-Moore, Shannon P ; Leach, Jeremiah ; Kendall, Ronald J

It has been demonstrated that helminths are capable of critically impacting the fitness of their hosts. This has typically been shown experimentally through the administration of anthelmintic drugs but are rarely performed on a landscape or host population scale. Here, the anthelmintic fenbendazole (FBZ) was mixed in a supplemental feed and provided to a free-ranging population of Northern bobwhite quail (Colinus virginianus). Abundances of Northern bobwhite and two nematode parasites commonly found infecting Northern bobwhite were monitored and compared to a neighboring untreated population. The Northern bobwhite population receiving the medicated feed grew substantially from 2019 to 2022, while the neighboring site had no change in abundance. The treated population was also substantially greater than the untreated population in 2021 and 2022. Additionally, the treated Northern bobwhite population had substantially lower abundances of the two nematodes. This research provides evidence of the ability of helminth populations to have a negative impact on Northern bobwhite populations and presents a method for reducing helminth abundance in those populations on a landscape scale.

2024-12-01·International Journal for Parasitology: Parasites and Wildlife

Identification and management of infections caused by Giardia sp., Trichuris sp. and Demodex sp. in captive Brazilian porcupines (Coendou prehensilis)

Article

作者: Frey, Caroline F ; Frey, Caroline F. ; Moré, Gastón ; Gliga, Diana S ; Rüegg-van den Broek, Peggy ; Glardon, Olivier J ; Basso, Walter ; Gliga, Diana S. ; Glardon, Olivier J.

The Brazilian porcupine (Coendou prehensilis, Rodentia, Erethizontidae) is an arboreal South American nocturnal rodent. Switzerland is home to one of the largest captive colonies in Europe. In June 2022, most of the animals in this colony showed severe diarrhoea, and Giardia sp. cysts were detected. All the animals were treated with metronidazole (75 mg/animal/day orally) for five days, repeating after two weeks. The diarrhoea continued, sometimes containing blood, and further analyses revealed Giardia sp. cysts and Trichuris sp. eggs with a particular undulating eggshell in pooled samples. The soil layer of some enclosures was removed to thoroughly clean and disinfect the underlying concrete floor. The animals were treated with fenbendazole (50 mg/kg/day orally) for 5 days repeating after three days. Giardia sp. cysts were not further detected. However, Trichuris sp. eggs were detected in branch bark samples and in six animals 2-3 months after treatment. The treatment with fenbendazole was repeated and no further Trichuris sp. eggs were detected. A 18S rRNA fragment consensus sequence showed 98.58% identity with Trichuris fossor. The Trichuris sp. in C. prehensilis may represent a new species, specific for arboreal porcupines. Demodex mites were observed in faecal flotations and thereafter in skin scrapings from five animals (four of them being family-related). A 16S consensus sequence showed 86.4% identity with other Demodex species. The animals were initially treated with moxidectin (0.4 and 0.8 mg/kg orally) and afterwards with sarolaner (10 mg/animal) but the treatments were not completely effective since in control scrapings, two animals evidenced few non-motile mites. An individual susceptibility and poor immunological control of the infection is suggested. Treatment with fenbendazole was effective against Giardia sp. and Trichuris sp. infections; however, reinfections may occur if the enclosures and tree branches are not deep cleaned and disinfected or replaced.

100 项与奥芬达唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05291	奥芬达唑	-	DB11446

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经系统囊虫病	临床3期	-	Universidad Peruana Cayetano Heredia	2024-12-15
神经系统囊虫病	临床3期	-	The Oxfendazole Development Group	2024-12-15
片形吸虫病	临床2期	-	National Institute of Allergy & Infectious Diseases	2025-01-30
鞭虫病	临床2期	-	The Oxfendazole Development Group	2024-07-01
丝虫病	临床1期	坦桑尼亚	Drugs for Neglected Diseases initiative	2022-04-21
眼盘尾丝虫病	临床1期	瑞士	Drugs for Neglected Diseases initiative	2022-01-30
蠕虫病	临床1期	美国	The Oxfendazole Development Group	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03035760 (CTgov)	临床1期	蠕虫病	36	Oxfendazole (Arm 1: 3 mg/kg Oxfendazole for 5 Days)	製積鹽廠淵鏇觸範憲鬱(鏇餘繭簾願觸淵範蓋鹽) = 齋積築憲願簾蓋憲夢網鑰夢餘窪壓鑰積艱獵艱 (遞壓齋憲醖簾鹹餘觸窪, 鹹鹽蓋鹹願壓蓋顧壓遞 ~ 積襯鬱廠醖鑰餘餘願膚) 更多	-	2019-12-17
				Oxfendazole (Arm 2: 7.5 mg/kg Oxfendazole for 5 Days)	製積鹽廠淵鏇觸範憲鬱(鏇餘繭簾願觸淵範蓋鹽) = 蓋窪遞憲簾糧願網選蓋鑰夢餘窪壓鑰積艱獵艱 (遞壓齋憲醖簾鹹餘觸窪, 蓋夢觸構築築衊選齋艱 ~ 淵蓋範構鬱鹽衊選鏇膚) 更多
NCT02234570 (CTgov)	临床1期	神经系统囊虫病	70	Oxfendazole (0.5 mg/kg Oxfendazole)	顧製鏇遞襯構餘觸構鑰(製壓積繭壓範壓簾鹽糧) = 願遞糧觸簾蓋簾繭艱艱鏇夢壓襯鹽築製餘餘齋 (淵構獵襯餘憲願鑰淵鑰, 鹹鹹膚鹽網網膚壓網衊 ~ 網膚鹽艱製願鹹鹽顧餘) 更多	-	2019-11-26
				Oxfendazole (1 mg/kg Oxfendazole)	顧製鏇遞襯構餘觸構鑰(製壓積繭壓範壓簾鹽糧) = 構積憲網願蓋鏇衊壓糧鏇夢壓襯鹽築製餘餘齋 (淵構獵襯餘憲願鑰淵鑰, 壓膚遞壓齋醖膚壓網襯 ~ 鏇鹽襯遞壓願夢餘壓壓) 更多
NCT02234570 (Pubmed \| Antimicrob Agents Chemother)	临床1期	-	70	Oxfendazole	(糧壓範築窪願獵製艱憲) = dose-dependent decrease 繭鑰窪淵餘獵鏇獵衊淵 (網鑰廠遞獵觸齋鹹壓網 ) 更多	-	2019-04-01